US FDA has finalized a pair of guidances that the agency hopes will spur development of databases that aggregate genomic data and advance the promising new diagnostics field of next-generation sequencing (NGS). The complementary guidances outline the agency's thinking on what sponsors need to consider when submitting pre-market applications for NGS tests and the databases that could be used to support the submissions.
FDA hopes the guidances could help revolutionize how patients are diagnosed with hereditary diseases or considered to be at higher risk for certain conditions
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Medtech Insight for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?